By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Azelastine (monograph)
Drugs

Azelastine (monograph)

https://themeditary.com/drug/azelastine-monograph-8316.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 29, 2023  Additional Content by TheMediTary.Com

Generic name: optivar

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Optivar, Azelastine ophthalmic

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Azelastine (monograph)?

Introduction

Relatively selective histamine H1-receptor antagonist; a phthalazinone derivative.

Uses for Azelastine

Seasonal Allergic Rhinitis

Symptomatic treatment of seasonal allergic rhinitis (e.g., hay fever). Intranasal azelastine is at least as effective as oral antihistamines (e.g., cetirizine) or intranasal corticosteroids. May provide improvement of ocular manifestations, possibly secondary to systemic absorption of the drug.

Nonallergic Rhinitis

Symptomatic treatment of nonallergic (vasomotor) rhinitis.

Allergic Conjunctivitis

Symptomatic relief of ocular itching associated with allergic conjunctivitis.

Related/similar drugs

prednisone, cetirizine ophthalmic, dexamethasone ophthalmic, prednisolone ophthalmic, doxylamine, Deltasone

Azelastine Dosage and Administration

Administration

Administer nasal solution intranasally twice daily, using a spray pump.

Apply ophthalmic solution topically to the eye twice daily. Ophthalmic solution is not for injection or oral use.

Intranasal Administration

Before initial use, prime the pump until a fine mist appears, using up to 4 actuations of the pump. Administration of solution in a stream of liquid rather than as a mist may fail to provide maximum benefit and may cause discomfort.

If inhaler has not been used for ≥3 days, reprime pump with 2 actuations or until a fine mist appears. Reprime pump when the spray pump is inserted into the second bottle.

To actuate the pump, hold the bottle in one hand, with 2 fingers on the shoulders of the pump unit and the thumb on the bottom of the bottle. Press the bottom firmly and rapidly upward with the thumb to produce a fine mist.

Prior to administration, gently blow the nose to clear nasal passages. Insert nasal spray tip ¼ to ½ inch into a nostril, tilt head slightly forward while holding the bottle vertically upright, and aim spray tip toward the back of the nose. Rapidly and firmly press and actuate pump into the nostril while holding the other nostril closed, gently sniffing at the same time; do not tilt head back after dosing.

Repeat procedure for the other nostril. Provide a second spray into each nostril, beginning with the first nostril. Alternate nostrils between each actuation of nasal spray.

Use caution to avoid spraying nasal spray into the eyes.

Ophthalmic Administration

Remove soft contact lenses prior to administration of each dose (since benzalkonium chloride may be absorbed by the lenses); may reinsert lenses 10 minutes after administration if eyes are not red.

Avoid contamination of the solution container.

Dosage

Available as azelastine hydrochloride; dosage expressed in terms of the salt.

When properly primed, the nasal spray pump delivers approximately 100 metered doses per bottle.

Pediatric Patients

Seasonal Allergic Rhinitis
Intranasal

Children ≥12 years of age: 2 sprays (274 mcg) in each nostril twice daily.

Children 5–11 years of age: 1 spray (137 mcg) in each nostril twice daily.

Nonallergic Rhinitis
Intranasal

Children ≥12 years of age: 2 sprays (274 mcg) in each nostril twice daily.

Allergic Conjunctivitis
Ophthalmic

Children ≥3 years of age: 1 drop of a 0.05% solution in the affected eye(s) twice daily.

Adults

Seasonal Allergic Rhinitis
Intranasal

2 sprays (274 mcg) in each nostril twice daily.

Nonallergic Rhinitis
Intranasal

2 sprays (274 mcg) in each nostril twice daily.

Allergic Conjunctivitis
Ophthalmic

1 drop of a 0.05% solution in the affected eye(s) twice daily.

Special Populations

Geriatric Patients

Cautious dosing of nasal solution recommended.

Detailed Azelastine ophthalmic dosage information

Warnings

Contraindications

  • Known hypersensitivity to azelastine or any ingredient in the formulation.

Warnings/Precautions

General Precautions

CNS Effects

Somnolence reported in patients receiving azelastine nasal solution. Performance of activities requiring mental alertness and physical coordination may be impaired.

Concurrent use of nasal solution with other CNS depressants may potentiate CNS depression. (See Specific Drugs under Interactions.)

Specific Populations

Pregnancy

Category C.

Lactation

Not known whether azelastine is distributed into milk. Use with caution in nursing women.

Pediatric Use

Safety and efficacy of nasal solution for treatment of seasonal allergic rhinitis not established in children <5 years of age; safety and efficacy for treatment of nonallergic rhinitis not established in children <12 years of age.

Safety and efficacy of ophthalmic solution not established in children <3 years of age.

Geriatric Use

Response to nasal solution does not appear to differ from that in younger adults.

No substantial differences in safety and efficacy of ophthalmic solution relative to younger adults.

Common Adverse Effects

Nasal solution: Transient nasal burning or stinging, bitter taste, somnolence, headache, pharyngitis, paroxysmal sneezing.

Ophthalmic solution: Transient ocular burning/stinging, bitter taste, headache.

How should I use Azelastine (monograph)

Administration

Administer nasal solution intranasally twice daily, using a spray pump.

Apply ophthalmic solution topically to the eye twice daily. Ophthalmic solution is not for injection or oral use.

Intranasal Administration

Before initial use, prime the pump until a fine mist appears, using up to 4 actuations of the pump. Administration of solution in a stream of liquid rather than as a mist may fail to provide maximum benefit and may cause discomfort.

If inhaler has not been used for ≥3 days, reprime pump with 2 actuations or until a fine mist appears. Reprime pump when the spray pump is inserted into the second bottle.

To actuate the pump, hold the bottle in one hand, with 2 fingers on the shoulders of the pump unit and the thumb on the bottom of the bottle. Press the bottom firmly and rapidly upward with the thumb to produce a fine mist.

Prior to administration, gently blow the nose to clear nasal passages. Insert nasal spray tip ¼ to ½ inch into a nostril, tilt head slightly forward while holding the bottle vertically upright, and aim spray tip toward the back of the nose. Rapidly and firmly press and actuate pump into the nostril while holding the other nostril closed, gently sniffing at the same time; do not tilt head back after dosing.

Repeat procedure for the other nostril. Provide a second spray into each nostril, beginning with the first nostril. Alternate nostrils between each actuation of nasal spray.

Use caution to avoid spraying nasal spray into the eyes.

Ophthalmic Administration

Remove soft contact lenses prior to administration of each dose (since benzalkonium chloride may be absorbed by the lenses); may reinsert lenses 10 minutes after administration if eyes are not red.

Avoid contamination of the solution container.

Dosage

Available as azelastine hydrochloride; dosage expressed in terms of the salt.

When properly primed, the nasal spray pump delivers approximately 100 metered doses per bottle.

Pediatric Patients

Seasonal Allergic Rhinitis
Intranasal

Children ≥12 years of age: 2 sprays (274 mcg) in each nostril twice daily.

Children 5–11 years of age: 1 spray (137 mcg) in each nostril twice daily.

Nonallergic Rhinitis
Intranasal

Children ≥12 years of age: 2 sprays (274 mcg) in each nostril twice daily.

Allergic Conjunctivitis
Ophthalmic

Children ≥3 years of age: 1 drop of a 0.05% solution in the affected eye(s) twice daily.

Adults

Seasonal Allergic Rhinitis
Intranasal

2 sprays (274 mcg) in each nostril twice daily.

Nonallergic Rhinitis
Intranasal

2 sprays (274 mcg) in each nostril twice daily.

Allergic Conjunctivitis
Ophthalmic

1 drop of a 0.05% solution in the affected eye(s) twice daily.

Special Populations

Geriatric Patients

Cautious dosing of nasal solution recommended.

Detailed Azelastine ophthalmic dosage information
Azelastine (monograph) Dosage information (more detail)

What other drugs will affect Azelastine (monograph)?

Metabolized by CYP isoenzymes.

Specific Drugs

Drug

Interaction

Comments

CNS depressants

Potential additive CNS depression with astelazine nasal solution

Avoid concomitant use

Cimetidine

Possible increased serum azelastine concentrations

Erythromycin

No pharmacokinetic interaction or effect on QTc observed

Ketoconazole

No pharmacokinetic interaction or effect on QTc observed

Ranitidine

No pharmacokinetic interaction observed

Theophylline

No pharmacokinetic interaction observed

More about Azelastine (monograph) (Optivar)

Dosage information
Azelastine (monograph) Side Effects
During pregnancy
Azelastine Ophthalmic Solution Prescribing Information
Drug images
Side effects
Drug class: Drugs

Related treatment guides

Conjunctivitis, Allergic
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by